News & Events

12/06/2018

The acquisition gives an added boost to Fidia’s leadership in the national and international ophthalmology market segment

Sooft is active in the treatment of all major eye conditions through Sooft, Bioos, Glaucoom, OftaH.T. e Neoox trademarks

The company owns 27 patents, further bolstering Fidia Pharma Group’s already strong portfolio, consisting of more than 900 patents, of which over 650 on hyaluronic acid

Abano Terme (PD), June 11, 2018 – Fidia Pharma Group, an Italian multinational company, leader in the R&D, manufacturing and sales of a wide range of products mainly based on hyaluronic acid, announced today the closing of the acquisition of Sooft, #1 Italian ophthalmic company in Italy , by…
25/04/2018

Poster Title: “Hyaluronan Derivative Hymovis® Increases Cartilage Volume and Type II Collagen Turnover in Osteoarthritis Knee:
Data from MOKHA (MRI, BiOmarkers, Knee, Hymovis®, OsteoArthritis) Study”

Potential beneficial effect of HYMOVIS® on pain and function

Structural modifying effect in knee OA with HYMOVIS®

Abano Terme, Italy, April 25, 2018 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announce that new data will be presented at the Osteoarthritis Research Society…
19/03/2018

Italian pharmaceutical R&D excellence at the 33rd Congress of the European Association of Urology

No new drug treatments for primary or recurrent papillary bladder cancer in 15 years

Oncofid®P-B is a Paclitaxel-Hyaluronan Bioconjugate developed and patented by Fidia farmaceutici, a leading Italian pharmaceutical multinational company

Copenhagen, March 18, 2018 – Fidia farmaceutici today announced the positive results from a phase II trial evaluating efficacy and tolerability of Oncofid®P-B, an innovative Paclitaxel-Hyaluronan Bioconjugate targeted to cancer cells, in patients with primary or recurrent Ta G1-G2 papillary bladder…
16/03/2018

Sleep problems may affect performance at work and quality of life, as well as have an impact on some chronic diseases

The “Sleep & Health” Project 2018 focuses on the cardiometabolic comorbidities of insomnia, and si dedicated to GPs and specialists (cardiologists, endocrinologists, geriatric physicians, diabetologists, neurologists, internists, and psychiatrists).

Insomnia and disruption of the sleep-wake cycle start a cascade of events that involve different organs, and have been associated with a wide range of deleterious health consequences, including an increased risk of hypertension, diabetes and obesity: an early identification of patients with sleep…
09/03/2018

Poster Title: Articular Cartilage Lubrication by HYADD®4 Reduces Tissue Strains, Chondrocyte Death, and Apoptosis

“This current study is consistent with the idea that hyaluronic acid therapies for arthritis may act in part through a mechanical pathway that preserves viability of chondrocytes at the cartilage surface,” states Dr. Bonassar.*

Florham Park, NJ, March 9, 2018 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA) based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces new data will be presented at the Annual Meeting of the Orthopaedic Research…
25/09/2017

Let's move, with Hymovis!

We are pleased to announce the release of our new www.hymovis.net website, designed with a user-friendly navigation, and updated with the latest information on the product. Our objective is to provide our international visitors with an easier way to learn about Hymovis and to browse information…
12/07/2017

Global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021

“Fidia Farmaceutici has invested in research and development of hyaluronic acid-based products for more than 70 years. Today, Fidia is growing its product portfolio with new, innovative solutions to meet challenges in the field of osteoarthritis using science, our legacy and our drive.”

PARSIPPANY, N.J.--(BUSINESS WIRE)--Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA Inc., are projecting continued growth in 2017. The global viscosupplementation market is…
17/03/2017

Management of sleep disorders may result in significant improvement of general health. The first step is talk to the primary care provider.

Social media use is rapidly increasing, as well as daytime and bedtime use of computers, including devices such as smartphones, tablets and laptops. Work, stress, menopause, advancing age or a variety of underlying medical conditions affecting the general population, may be responsible for those…
28/02/2017

The Company is finalizing the acquisition of Italian Sooft/Oox Group

As announced at the end of 2016, Fidia has finalized the first step to the successful acquisition of the majority stake in the Sooft/Oox Group, through a legally binding agreement that will be executed over the next few weeks. Sooft/Oox is an Italian group active in the ophthalmic sector, with a…
10/01/2017

An update from Fidia Farmaceutici

Further to previous communications, regarding the development of a hair loss remedy initiated a few months ago, we announce that the study is still in progress, thereby an accurate time frame in which such remedy would be available cannot be defined yet. Being a pharmaceutical manufacturing company…

Health
Products
Website

Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- ophthalmology
- wound care
- dermatology
- neurology
- dermo-aesthetics